Awen Oncology

Awen Oncology is a Welsh oncology biotechnology company developing first-in-class therapeutics that target cancer-specific proteins derived from developmental genes that are dormant in healthy adult tissue but aberrantly reactivated in tumour cells.

The company's platform integrates high-throughput cell and molecular biology with computational medicinal chemistry to identify and progress novel inhibitors across multiple cancer types, including rare malignancies with no current treatment options.